Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

Cellular and Molecular Life Sciences

Volumn 73, Issue 2, 2016, Pages 377-392

  Li, Zhaoyong ^a   Zhang, Huafeng ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Amino acid; Cancer; Fatty acid; Glucose; Metabolism

Indexed keywords

AMINO ACID; FATTY ACID; GLUCOSE;

ANIMAL; GLYCOLYSIS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY;

AMINO ACIDS; ANIMALS; FATTY ACIDS; GLUCOSE; GLYCOLYSIS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 84954044571     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-015-2070-4     Document Type: Review

References (165)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
2. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309-314
3. Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269-270
4. Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27:441-464
5. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029-1033
6. Wellen KE et al (2010) The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 24(24):2784-2799
7. Gao P, Sun L, He X, Cao Y, Zhang H (2012) MicroRNAs and the Warburg effect: new players in an old arena. Curr Gene Ther 12(4):285-291
8. Kim JW et al (2004) Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 24(13):5923-5936
9. Mikawa T et al (2015) Dysregulated glycolysis as an oncogenic event. Cell Mol Life Sci 72(10):1881-1892
10. Li F et al (2005) Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25(14):6225-6234
11. Sun L et al (2015) cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res 25(4):429-444
12. Graven KK, Yu Q, Pan D, Roncarati JS, Farber HW (1999) Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim Biophys Acta 1447(2-3):208-218
13. Zhang JY et al (2015) Critical protein GAPDH and its regulatory mechanisms in cancer cells. Cancer Biol Med 12(1):10-22
14. Kress S et al (1998) Expression of hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol 124(6):315-320
15. Huang D, Li C, Zhang H (2014) Hypoxia and cancer cell metabolism. Acta Biochim Biophys Sin 46(3):214-219
16. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E (2004) The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64(7):2627-2633
17. Zhang C et al (2014) Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget 5(14):5535-5546
18. Mikawa T et al (2014) Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. J Cell Biol 204(5):729-745
19. Bensaad K et al (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126(1):107-120
20. Yuan H, Su L, Chen WY (2013) The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 6:1399-1416
21. German NJ, Haigis MC (2015) Sirtuins and the Metabolic Hurdles in Cancer. Curr Biol 25(13):R569-R583
22. Zwaans BM, Lombard DB (2014) Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis Model Mech 7(9):1023-1032
23. Hallows WC, Yu W, Denu JM (2012) Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J Biol Chem 287(6):3850-3858
24. Tsusaka T et al (2014) Deacetylation of phosphoglycerate mutase in its distinct central region by SIRT2 down-regulates its enzymatic activity. Genes Cells 19(10):766-777
25. Xu Y et al (2014) Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res 74(13):3630-3642
26. Houtkooper RH, Pirinen E, Auwerx J (2012) Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13(4):225-238
27. Sun L, He X, Cao Y, Gao P, Zhang H (2014) MicroRNAs and energy metabolism in cancer cells, chapter 4. In: Babashah S (ed) MicroRNAs: key regulators of oncogenesis. Springer, Switzerland, pp 84-95
28. Hung CL et al (2014) A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci USA 111(52):18697-18702
29. Vander Heiden MG et al (2011) Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol 76:325-334
30. Dang CV (2012) Links between metabolism and cancer. Genes Dev 26(9):877-890
31. Boroughs LK, DeBerardinis RJ (2015) Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17(4):351-359
32. Chen B et al (2015) miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett 356(2 pt B):410-417
33. Rathmell JC et al (2003) Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23(20):7315-7328
34. Wieman HL, Wofford JA, Rathmell JC (2007) Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 18(4):1437-1446
35. Morani F et al (2014) PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. J Mol Endocrinol 53(2):247-258
36. Goos JA et al (2015) Glucose transporter 1 (SLC2A1) and vascular endothelial growth factor A (VEGFA) predict survival after resection of colorectal cancer liver metastasis. Ann Surg. doi: 10.1097/SLA.0000000000001109
37. Kawauchi K, Araki K, Tobiume K, Tanaka N (2008) p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10(5):611-618
38. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(34):4777-4786
39. Kim HR, Roe JS, Lee JE, Cho EJ, Youn HD (2013) p53 regulates glucose metabolism by miR-34a. Biochem Biophys Res Commun 437(2):225-231
40. Peschiaroli A et al (2013) miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 32(6):797-802
41. Wang L et al (2014) Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep 8(5):1461-1474
42. Li Z, Li X, Wu S, Xue M, Chen W (2014) Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci 105(8):951-955
43. Du S et al (2014) Fructose-bisphosphate aldolase a is a potential metastasis-associated marker of lung squamous cell carcinoma and promotes lung cell tumorigenesis and migration. PLoS One 9(1):e85804
44. Long F, Cai X, Luo W, Chen L, Li K (2014) Role of aldolase A in osteosarcoma progression and metastasis: in vitro and in vivo evidence. Oncol Rep 32(5):2031-2037
45. Sun Y, Long J, Zhou Y (2014) Angiopoietin-like 4 promotes melanoma cell invasion and survival through aldolase A. Oncol Lett 8(1):211-217
46. Guo C, Liu S, Sun MZ (2013) Novel insight into the role of GAPDH playing in tumor. Clin Transl Oncol 15(3):167-172
47. Ramos D et al (2015) Deregulation of glyceraldehyde-3-phosphate dehydrogenase expression during tumor progression of human cutaneous melanoma. Anticancer Res 35(1):439-444
48. Li T et al (2014) Glyceraldehyde-3-phosphate dehydrogenase is activated by lysine 254 acetylation in response to glucose signal. J Biol Chem 289(6):3775-3785
49. Colell A et al (2007) GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 129(5):983-997
50. Jiang X, Sun Q, Li H, Li K, Ren X (2014) The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications. Int J Cancer 135(9):1991-1996
51. Hitosugi T et al (2012) Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22(5):585-600
52. Le A et al (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107(5):2037-2042
53. Liu X et al (2015) Effects of the suppression of lactate dehydrogenase A on the growth and invasion of human gastric cancer cells. Oncol Rep 33(1):157-162
54. Li X, Zhao H, Zhou X, Song L (2015) Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. Mol Med Rep 11(1):577-582
55. McCleland ML et al (2012) An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 72(22):5812-5823
56. Tambe Y, Hasebe M, Kim CJ, Yamamoto A, Inoue H (2015) The drs tumor suppressor regulates glucose metabolism via lactate dehydrogenase-B. Mol Carcinog. doi: 10.1002/mc.22258
57. Jiang P, Du W, Wu M (2014) Regulation of the pentose phosphate pathway in cancer. Protein Cell 5(8):592-602
58. Nogueira V, Hay N (2013) Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res 19(16):4309-4314
59. Jiang P et al (2011) p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13(3):310-316
60. Hong X et al (2014) PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut 63(10):1635-1647
61. Patra KC, Hay N (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39(8):347-354
62. Patra KC et al (2013) Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24(2):213-228
63. Yi W et al (2012) Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 337(6097):975-980
64. Anastasiou D et al (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334(6060):1278-1283
65. Fukuda S et al (2015) Pyruvate kinase M2 modulates esophageal squamous cell carcinoma chemotherapy response by regulating the pentose phosphate pathway. Ann Surg Oncol. doi: 10.1245/s10434-015-4522-3
66. DeBerardinis RJ (2011) Serine metabolism: some tumors take the road less traveled. Cell Metab 14(3):285-286
67. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G (2014) Serine and glycine metabolism in cancer. Trends Biochem Sci 39(4):191-198
68. Zhang H et al (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11(5):407-420
69. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3(3):177-185
70. Ma X et al (2014) Lin28/let-7 axis regulates aerobic glycolysis and cancer progression via PDK1. Nat Commun 5:5212
71. Swierczynski J, Hebanowska A, Sledzinski T (2014) Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol 20(9):2279-2303
72. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18(2):153-161
73. Catalina-Rodriguez O et al (2012) The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget 3(10):1220-1235
74. Ozkaya AB, Ak H, Atay S, Aydin HH (2015) Targeting mitochondrial citrate transport in breast cancer cell lines. Anti-Cancer Agents Med Chem 15(3):374-381
75. Wellen KE et al (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324(5930):1076-1080
76. Zhou Y et al (2013) ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther 12(12):2782-2791
77. Szutowicz A, Kwiatkowski J, Angielski S (1979) Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br J Cancer 39(6):681-687
78. Beckner ME et al (2010) Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer 126(10):2282-2295
79. Wang Y et al (2012) Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer. Oncol Rep 27(4):1156-1162
80. Zaidi N, Swinnen JV, Smans K (2012) ATP-citrate lyase: a key player in cancer metabolism. Cancer Res 72(15):3709-3714
81. Hanai J et al (2012) Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol 227(4):1709-1720
82. Zong H, Zhang Y, You Y, Cai T, Wang Y (2015) Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer. Med Oncol 32(3):85
83. Lin R et al (2013) Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell 51(4):506-518
84. Lee JH et al (2015) ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway. FEBS J 282(2):361-371
85. Bourbeau MP, Bartberger MD (2015) Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease. J Med Chem 58(2):525-536
86. Shaw RJ et al (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101(10):3329-3335
87. Carling D, Zammit VA, Hardie DG (1987) A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 223(2):217-222
88. Laurent G et al (2013) SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell 50(5):686-698
89. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763-777
90. Hopperton KE, Duncan RE, Bazinet RP, Archer MC (2014) Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Exp Cell Res 320(2):302-310
91. Knobloch M et al (2013) Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis. Nature 493(7431):226-230
92. Sun Y et al (2015) SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism. Tumour Biol 36(6):4133-4141
93. Elhanati S et al (2013) Multiple regulatory layers of SREBP1/2 by SIRT6. Cell Rep 4(5):905-912
94. Lin L et al (2014) SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis. Oncol Rep 32(6):2831-2835
95. Porstmann T et al (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8(3):224-236
96. Li S, Oh YT, Yue P, Khuri FR, Sun SY (2015) Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene. doi: 10.1038/onc.2015.123
97. Lyssiotis CA, Cantley LC (2014) Acetate fuels the cancer engine. Cell 159(7):1492-1494
98. Comerford SA et al (2014) Acetate dependence of tumors. Cell 159(7):1591-1602
99. Mashimo T et al (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159(7):1603-1614
100. Maher EA et al (2012) Metabolism of [U-13 C] glucose in human brain tumors in vivo. NMR Biomed 25(11):1234-1244
101. Zhang X et al (2015) Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. J Lipid Res 56(5):963-971
102. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109(9):1125-1131
103. Shamma A et al (2009) Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 15(4):255-269
104. Freed-Pastor WA et al (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148(1-2):244-258
105. Singh R, Cuervo AM (2012) Lipophagy: connecting autophagy and lipid metabolism. Int J Cell Biol 2012:282041
106. Yan S et al (2015) Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update. World J Gastroenterol 21(12):3492-3498
107. Liang YC et al (2005) Involvement of fatty acid-CoA ligase 4 in hepatocellular carcinoma growth: roles of cyclic AMP and p38 mitogen-activated protein kinase. World J Gastroenterol 11(17):2557-2563
108. Wu X et al (2013) Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS One 8(10):e77060
109. Huang D et al (2014) HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep 8(6):1930-1942
110. Hassanein M et al (2013) SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 19(3):560-570
111. Mates JM et al (2013) Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med 13(4):514-534
112. Gao P et al (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762-765
113. Wise DR et al (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105(48):18782-18787
114. Suzuki S et al (2010) Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 107(16):7461-7466
115. Son J et al (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496(7443):101-105
116. Le A et al (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15(1):110-121
117. Faubert B et al (2014) Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proc Natl Acad Sci USA 111(7):2554-2559
118. DeBerardinis RJ et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104(49):19345-19350
119. Yang C et al (2014) Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell 56(3):414-424
120. Nikiforov MA et al (2002) A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol Cell Biol 22(16):5793-5800
121. Labuschagne CF, van den Broek NJ, Mackay GM, Vousden KH, Maddocks OD (2014) Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep 7(4):1248-1258
122. Phang JM, Liu W, Hancock CN, Fischer JW (2015) Proline metabolism and cancer: emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care 18(1):71-77
123. Phang JM, Liu W, Hancock C, Christian KJ (2012) The proline regulatory axis and cancer. Front Oncol 2:60
124. Togashi Y et al (2014) Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget 5(10):2962-2973
125. Scott L, Lamb J, Smith S, Wheatley DN (2000) Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 83(6):800-810
126. Kuo MT, Savaraj N, Feun LG (2010) Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 1(4):246-251
127. Feun LG, Kuo MT, Savaraj N (2015) Arginine deprivation in cancer therapy. Curr Opin Clin Nutr Metab Care 18(1):78-82
128. Moon JS et al (2011) Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 433(1):225-233
129. Metallo CM et al (2012) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481(7381):380-384
130. Mullen AR et al (2012) Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481(7381):385-388
131. Sun RC, Denko NC (2014) Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 19(2):285-292
132. Chaneton B et al (2012) Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491(7424):458-462
133. Ye J et al (2012) Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA 109(18):6904-6909
134. Suzuki M et al (2015) Glycolytic flux controls d-serine synthesis through glyceraldehyde-3-phosphate dehydrogenase in astrocytes. Proc Natl Acad Sci USA 112(17):E2217-E2224
135. Gomes AP, Blenis J (2015) A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways. Curr Opin Biotechnol 34C:110-117
136. Hu JW, Sun P, Zhang DX, Xiong WJ, Mi J (2014) Hexokinase 2 regulates G1/S checkpoint through CDK2 in cancer-associated fibroblasts. Cell Signal 26(10):2210-2216
137. Al Hasawi N, Alkandari MF, Luqmani YA (2014) Phosphofructokinase: a mediator of glycolytic flux in cancer progression. Crit Rev Oncol Hematol 92(3):312-321
138. Enzo E et al (2015) Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J 34(10):1349-1370
139. Sun Q et al (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108(10):4129-4134
140. Vander Heiden MG et al (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329(5998):1492-1499
141. Anastasiou D et al (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 8(10):839-847
142. Israelsen WJ et al (2013) PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155(2):397-409
143. Palsson-McDermott EM et al (2015) Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab 21(1):65-80
144. Dong T et al (2015) Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1alpha and Bcl-xL in culture. Biomed Pharmacother 69:277-284
145. Yang P, Li Z, Fu R, Wu H, Li Z (2014) Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell Signal 26(9):1853-1862
146. Hu W et al (2015) Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Oncotarget 6(9):6570-6583
147. Yang P et al (2015) Secreted pyruvate kinase M2 facilitates cell migration via PI3K/Akt and Wnt/beta-catenin pathway in colon cancer cells. Biochem Biophys Res Commun 459(2):327-332
148. Ritterson Lew C, Tolan DR (2012) Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J Biol Chem 287(51):42554-42563
149. Caspi M et al (2014) Aldolase positively regulates of the canonical Wnt signaling pathway. Mol Cancer 13:164
150. Fu QF et al (2015) Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol 8(1):22
151. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12(11):829-846
152. Liu Y et al (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11(8):1672-1682
153. Zhan T, Digel M, Kuch EM, Stremmel W, Fullekrug J (2011) Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J Cell Biochem 112(3):849-859
154. Klippel S et al (2012) Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol 159(3):340-351
155. Clem BF et al (2013) Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther 12(8):1461-1470
156. Zhang D et al (2014) 2-Deoxy-d-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett 355(2):176-183
157. Hanai JI, Doro N, Seth P, Sukhatme VP (2013) ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death Dis 4:e696
158. Pandey PR, Liu W, Xing F, Fukuda K, Watabe K (2012) Anti-cancer drugs targeting fatty acid synthase (FAS). Recent Pat Anti Cancer Drug Discov 7(2):185-197
159. Fako VE, Wu X, Pflug B, Liu JY, Zhang JT (2015) Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. J Med Chem 58(2):778-784
160. Weinberg SE, Chandel NS (2015) Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 11(1):9-15
161. Wang JB et al (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18(3):207-219
162. Korangath P et al (2015) Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res 21(14):3263-3273
163. Wang Q et al (2015) Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol 236(3):278-289
164. Jain M et al (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336(6084):1040-1044
165. Schwartz L et al (2013) Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin. Invest New Drugs 31(2):256-264